TOUCH II期试验:HR阳性/HER2阳性早期乳腺癌新辅助无化疗方案与紫杉醇比较
TOUCH是一项国际开放标签II期试验,入组绝经后cT>1cm、cN0或cN1的HR阳性/HER2阳性乳腺癌患者,随机接受16周每周紫杉醇或哌柏西利+来曲唑,均联合曲妥珠单抗+帕妥珠单抗。主要假设RBsig与pCR存在交互作用未获支持(P=0.18),但无化疗骨架的pCR率与紫杉醇相似(33.3% vs 32.9%)。
要点
- 哌柏西利+来曲唑+双靶向的pCR率33.3%,与紫杉醇+双靶向的32.9%相近。
- RBsig与治疗对pCR无显著交互作用(P=0.18),主要假设未获支持。
- 非luminal型pCR高于luminal型(45.5% vs 18.4%),与治疗无交互。
核心结论
- 主要假设未获支持,但哌柏西利+来曲唑联合双靶向的无化疗方案pCR率与紫杉醇相似,为有吸引力的替代策略。
研究设计与样本
- 国际、开放标签、随机II期试验,入组绝经后cT>1cm、cN0或cN1的HR阳性/HER2阳性乳腺癌患者。
- 随机分配至16周新辅助每周紫杉醇或哌柏西利+来曲唑,均联合曲妥珠单抗+帕妥珠单抗(HP)。
- 共147例随机(紫杉醇+HP 74例,哌柏西利+来曲唑+HP 73例),145例构成治疗人群,中位年龄69岁(IQR 63-73)。
- 主要目标为E2F通路活性基因签名(RBsig)与pCR(ypT0N0或ypTisN0)的交互作用,采用逻辑回归在115例可评估患者中分析。
主要发现
- pCR率在紫杉醇+HP组为32.9%(95%CI 22.3%-44.9%),在哌柏西利+来曲唑+HP组为33.3%(95%CI 22.7%-45.4%)。
- RBsig与治疗交互作用不显著(P=0.18):紫杉醇+HP组RBsig高 vs 低pCR为31.3%(95%CI 16.1%-50.0%) vs 42.3%(95%CI 23.4%-63.1%);哌柏西利组为38.5%(95%CI 20.2%-59.4%) vs 25.8%(95%CI 11.9%-44.6%)。
- 非luminal型 vs luminal型pCR为45.5% vs 18.4%,与治疗无交互作用。
- 哌柏西利组完成治疗比例高于紫杉醇组(94.4% vs 79.5%)。
- 最常见3-4级不良事件为中性粒细胞减少和腹泻:紫杉醇+HP组 vs 哌柏西利+来曲唑+HP组分别为6.9% vs 43.1%和11% vs 8.3%。
临床怎么用
- 对于绝经后HR阳性/HER2阳性早期乳腺癌,哌柏西利+来曲唑联合双靶向可作为免化疗的新辅助治疗选择,pCR率与紫杉醇联合双靶向相当。
局限性
- II期试验样本量有限,主要假设未达统计学显著,结果需进一步验证。
- RBsig可评估患者为115例,并非全部随机人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) is a heterogeneous disease with low pathological complete response (pCR) to standard neoadjuvant treatment. Cyclin-dependent kinase 4 and 6 inhibitors with endocrine and anti-HER2 therapy have shown a potential for chemotherapy omission in this context. PATIENTS AND METHODS: TOUCH is an international, open-label, phase II trial for postmenopausal patients with cT >1 cm, cN0 or cN1, HR-positive/HER2-positive BC, randomly assigned to 16 weeks of neoadjuvant weekly paclitaxel or palbociclib and letrozole, both with trastuzumab + pertuzumab (HP). The primary objective investigated the interaction between a gene signature of E2F pathway activity (RBsig) and pCR (ypT0N0 or ypTisN0), hypothesizing higher pCR for RBsig-high tumors in the paclitaxel + HP group and for RBsig-low tumors in the palbociclib + letrozole + HP group. RBsig was assessed by RNA-sequencing from pre-treatment biopsies; intrinsic subtypes were estimated by absolute intrinsic molecular subtyping Treatment-by-biomarker interaction was estimated using logistic regression in 115 assessable patients. RESULTS: A total of 147 patients were randomly assigned (74 paclitaxel + HP, 73 palbociclib + letrozole + HP) and 145 constituted the treated population, with a median age of 69 years (interquartile range 63-73 years). More patients completed palbociclib versus paclitaxel (94.4% versus 79.5%). The most frequent grade 3-4 adverse events were neutropenia and diarrhea (6.9% versus 43.1% and 11% versus 8.3% in the paclitaxel + HP versus the palbociclib + letrozole + HP groups, respectively). The pCR rate was 32.9% [95% confidence interval (CI) 22.3% to 44.9%] in the paclitaxel + HP group and 33.3% (95% CI 22.7% to 45.4%) in the palbociclib + letrozole + HP group. No significant treatment-by-RBsig interaction was observed (P = 0.18): pCR in RBsig high versus low was 31.3% (95% CI 16.1% to 50.0%) versus 42.3% (95% CI 23.4% to 63.1%) in the paclitaxel + HP group, and 38.5% (95% CI 20.2% to 59.4%) versus 25.8% (95% CI 11.9% to 44.6%) in the palbociclib group. pCR was higher in non-luminal versus luminal subtypes (45.5% versus 18.4%), with no interaction with treatment. CONCLUSIONS: Although the primary hypothesis was not supported, TOUCH shows that dual anti-HER2 blockade with a chemotherapy-free backbone of palbociclib + letrozole yields pCR rates similar to paclitaxel, representing an attractive alternative treatment strategy.
引用
- Malorni L, Tyekucheva S, Gombos A, et al. Palbociclib plus letrozole versus weekly paclitaxel, both in combination with trastuzumab plus pertuzumab, as neoadjuvant treatment for patients with HR-positive/HER2-positive early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55-17). Ann Oncol. 2025. PMID: 41109527. doi:10.1016/j.annonc.2025.10.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。